app ratio
Recently Published Documents


TOTAL DOCUMENTS

6
(FIVE YEARS 2)

H-INDEX

1
(FIVE YEARS 0)

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Tamires Alves Sarno ◽  
Leda Leme Talib ◽  
Helena Passarelli Giroud Joaquim ◽  
Marcia Radanovic ◽  
Jessyka Maria de França Bram ◽  
...  

2020 ◽  
Vol 21 (14) ◽  
pp. 5110
Author(s):  
Tiziana Casoli ◽  
Cinzia Giuli ◽  
Marta Balietti ◽  
Paolo Fabbietti ◽  
Fiorenzo Conti

In patients with Alzheimer’s disease (AD), synaptic plasticity seems to be involved in cognitive improvement induced by cognitive training. The platelet amyloid precursor protein (APP) ratio (APPr), i.e., the ratio between two APP isoforms, may be a useful peripheral biomarker to investigate synaptic plasticity pathways. This study evaluates the changes in neuropsychological/cognitive performance and APPr induced by cognitive training in AD patients participating in the “My Mind Project”. Neuropsychological/cognitive variables and APPr were evaluated in the trained group (n = 28) before a two-month experimental protocol, immediately after its termination at follow-up 1 (FU1), after 6 months at follow-up 2 (FU2), and after 24 months at follow-up 3 (FU3). The control group (n = 31) received general psychoeducational training for two months. Some memory and attention parameters were significantly improved in trained vs. control patients at FU1 and FU2 compared to baseline (Δ values). At FU3, APPr and Mini Mental State Examination (MMSE) scores decreased in trained patients. Δ APPr correlated significantly with the Δ scores of (i) MMSE at FU1, (ii) the prose memory test at FU2, and (iii) Instrumental Activities of Daily Living (IADL), the semantic word fluency test, Clinical Dementia Rating (CDR), and the attentive matrices test at FU3. Our data demonstrate that the platelet APPr correlates with key clinical variables, thereby proving that it may be a reliable biomarker of brain function in AD patients.


2014 ◽  
Vol 10 ◽  
pp. P794-P794
Author(s):  
Tamires Alves Sarno ◽  
Helena Passarelli Giroud Joaquim ◽  
Leda Leme Talib ◽  
Sergio Hototian ◽  
Wagner Gattaz ◽  
...  
Keyword(s):  

2006 ◽  
Vol 22 (3) ◽  
pp. 119-125 ◽  
Author(s):  
V. J. Sánchez-González ◽  
G. G. Ortiz ◽  
P. Gallegos-Arreola ◽  
M. A. Macías-Islas ◽  
E. D. Arias-Merino ◽  
...  

Objective: To determine theβ-amyloid precursor protein (βAPP) isoforms ratio as a risk factor for Alzheimer’s Disease and to assess its relationship with demographic and genetic variables of the disease.Methods: Blood samples from 26 patients fulfilling NINCDS-ADRDA diagnostic criteria for AD and 46 healthy control subjects were collected for Western blotting forβAPP. A ratio ofβAPP isoforms, in optical densities, between the upper band (130 Kd) and the lower bands (106–110 Kd) was obtained. Odds ratios were obtained to determine risk factor of this component.Results:βAPP ratio on AD subjects was lower than that of control subjects: 0.3662 ± 0.1891 vs. 0.6769 ± 0.1021 (mean ± SD, p<0.05). A lowβAPP ratio (<0.6) showed an OR of 4.63 (95% CI 1.45 ± 15.33). When onset of disease was taken into account, aβAPP ratio on EOAD subjects of 0.3965 ± 0.1916 was found vs. 0.3445 ± 0.1965 on LOAD subjects (p>0.05).Conclusions: AlteredβAPP isoforms is a high risk factor for Alzheimer’s disease, although it has no influence on the time of onset of the disease.


Sign in / Sign up

Export Citation Format

Share Document